T
Taligen Therapeutics
Focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases
About Taligen Therapeutics
Taligen Therapeutics was a development-stage biotechnology firm founded in 2004 and headquartered in Cambridge, Massachusetts. The company focused on creating new treatments for immune and inflammatory diseases by regulating the complement system, a crucial part of the immune pathway. Its core business revolved around developing a pipeline of protein therapeutics, including monoclonal antibodies and fusion proteins, designed to selectively target and control excessive inflammation in affected tissues. This approach was applicable to a wide range of conditions, from genetic and orphan diseases to large-market ailments like age-related macular degeneration (AMD).
The company's strategy centered on its proprietary technology related to complement biology. Taligen's lead product candidate was TT30, a novel fusion protein that selectively binds to complement-activated cells to regulate the immune system locally. This product and other related compounds were covered by U.S. Patent No. 7,759,304, which was exclusively licensed to Taligen from the Medical University of South Carolina and the University of Colorado. The company's business model was to use its development platform to achieve proof-of-concept in smaller trials for rare diseases and then form partnerships with larger pharmaceutical companies for broader market applications.
Under the leadership of President and CEO Abbie Celniker, Ph.D., who joined in 2008, Taligen secured significant venture capital funding. Dr. Celniker brought extensive experience from senior R&D and leadership roles at companies like Novartis and Millennium Pharmaceuticals. The company raised a total of $101 million over three funding rounds, with investors including Alta Partners, Sanderling Ventures, and Blackstone. A significant milestone was the company's acquisition by Alexion Pharmaceuticals in January 2011 for an upfront cash payment of $111 million. The deal also included potential future payments based on achieving clinical and regulatory milestones for up to six products. Following the acquisition, Taligen's scientific team became the core of Alexion's new Translational Medicine Group, also headed by Dr. Celniker, to continue the development of Taligen's promising preclinical compounds.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2004
- Headquarters
- Cambridge, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 59.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Inflammatory Diseases, Spinout, Alternative Protein, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2011 | $111M | $111M | Alexion Pharmaceuticals | — |
| SERIES BOther financing | Aug 2010 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for Taligen Therapeutics is 0 monthly website visits. Taligen Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Taligen Therapeutics in the Cambridge ecosystem
The Taligen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- HVHigh Country Venture
Alta Partners
Other known investors4 additional known investors
Alexion Pharmaceuticals
Medical University of South Carolina
National Jewish Health Respiratory Institute
University of Colorado
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Taligen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Taligen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









